Finance entity
markets is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Keytruda, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Keytruda, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The 8 average consequence score is above the beat benchmark of 6.3 in the same window. We currently track 2 Finance stories that mention TERN-701, all published on March 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 84 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TERN-701. Shared-story counts are live from our verified record — not editorial picks.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
TERN-701 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
